STL001

STL001 is a novel, potent, and selective small molecule inhibitor of forkhead box protein M1 (FOXM1), a transcription factor implicated in tumor proliferation, therapy resistance, and poor clinical outcomes across various cancer types. It promotes the translocation of nuclear FOXM1 to the cytoplasm and induces its autophagic degradation. STL001 selectively downregulates FOXM1 protein levels and associated regulatory pathways in a wide range of human cancers, including ovarian, colorectal, esophageal, breast (both hormone receptor-positive and triple negative), prostate, and acute myeloid leukemia. Preclinical studies show STL001 sensitizes these cancers to conventional chemotherapy, targeted therapies, and immunotherapies, without prominent cytotoxic activity on its own. It demonstrates up to 50-fold increased potency over its predecessor, STL427944. Its unique mechanism, targeting chemotherapy-induced and endogenous FOXM1, primes resistant cancers for improved therapeutic responses and supports combination therapy strategies[1][3][4][5][7][8][9][10].

Other names

BiTE-hIgFcanti-CD3 x anti-CD138 bispecific antibodyanti-CD-3 x anti-CD138 bispecific antibodyanti-CD 3 x anti-CD138 bispecific antibody